PIK3CD and breast carcinoma: The combined inhibition of fatty acid synthase (FASN) and PI3Kα triggers a synergistic anti-tumor effect in 4T1 breast cancer cells, further reinforcing the need to use isoform-specific PI3K inhibitors in combination with other targeted therapies in cancer [25].